临床试验/NCT05650385

NCT05650385尚未招募1 期

A Multicenter, Open-label, Dose-escalating Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

Tasly Biopharmaceuticals Co., Ltd.1 个研究点分布在 1 个国家目标入组 68 人开始时间: 2022年12月最近更新: 2022年12月14日

适应症

干预措施

试验速览

阶段: 1 期
状态: 尚未招募
发起方: Tasly Biopharmaceuticals Co., Ltd.
入组人数: 68
试验地点: 1
主要终点: DLT Assessment

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is to characterize the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of B1962, a PD-L1/VEGF bispecific antibody fusion protein, as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of two parts: a once-weekly (QW) dosing phase and a biweekly (Q2W) dosing phase, which will explore the possibility of Q2W dosing of B1962 based on the PK data obtained in the QW phase. The study will determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for B1962 as a single agent.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Sequential
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•written and signed informed consent.
•Age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form.
•Patients with histologically or cytologically confirmed advanced malignant solid tumors who have failed or failed to respond to standard therapy, or who are intolerant of standard therapy, or who have no standard effective treatment regimen, or who have refused standard therapy (posterior and endline).
•willing and able to comply with all study procedures.
•Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or
•Life expectancy ≥ 3 months.
•Subjects must have at least one measurable lesion according to RECIST Version 1.1
•Adequate organ and bone marrow function
•Females of childbearing potential and non-sterilized males who are sexually active must use an effective method of contraception from screening until 120 days after final dose of investigational product or women of non child bearing potential.

排除标准

•Patients receiving immune checkpoint inhibitors (ICIs) or VEGF/VEGFR inhibitors within 28 days prior to the first dose of the study drug.
•Known allergy or reaction to any component of the B1962 formulation or history of severe hypersensitivity reactions to other large protein agents/mAbs or BsAbs.
•Female patients who are pregnant or breastfeeding.
•Subjects has received major surgical procedure within 4 weeks prior to the first dose of B1962, or is scheduled to receive major surgical procedure during the current study period
•Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1 (except for alopecia).
•Patients with untreated or clinically symptomatic brain metastases, spinal cord compression, cancerous meningitis, or other evidence that the patient's brain or spinal cord metastases have not been controlled (except in cases where the patient has been treated and has stable symptoms, imaging shows stability for at least 4 weeks prior to the first dose, and there is no evidence of brain edema and no need for glucocorticoid therapies)
•Patients with clinically symptomatic or recurrent pleural effusions, pericardial effusions or ascites requiring repeated drainage
•Imaging at the screening period showed that the tumor was wrapped around important blood vessels or had significant necrosis or cavitiation, and the investigators judged that entering the study would cause bleeding risk
•Known history of HIV infection or acquired immunodeficiency syndrome-related disease
•Patients with hepatitis B or C infection; or known active syphilis infection.
•Uncontrolled infections requiring systemic therapy within 4 weeks prior to the first dose of study drug.
•Subjects with clinically significant cardiovascular disease; uncontrolled hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) or poor compliance with antihypertensive therapy; major vascular disease.
•History of Coagulation disorders, bleeding disorders, or other conditions judged by the investigator to be a risk of bleeding within 6 months prior to the first dose.
•pulmonary hemorrhage/hemoptysis ≥ grade 2 (according to NCI-CTCAE v5.0) within 1 month prior to first drug administration
•biopsy or other minor surgery, excluding placement of vascular access devices, within 7 days prior to the first dose of B1962
•History of arterial or venous thrombosis, or stroke or transient ischemic attack within 6 months prior to the first dose of B1962
•Current unstable dose of anticoagulant or thrombolytic medication within 14 days of the first dose of B
•Note: prophylactic use of low molecular heparin is acceptable.
•Aspirin (> 325 mg/day) or NSAIDs treatment within 14 days of first dose of B1962
•Uncontrolled diabetes mellitus (HbA1c >8%) on standard therapy
•Active or prior documented idiopathic pulmonary fibrosis or idiopathicpneumonia; current acute lung disease, interstitial lung disease or pneumonia (except localized interstitial pneumonia due to radiotherapy induction), pulmonary fibrosis, etc.; severe respiratory distress, pulmonary insufficiency or continuous oxygenation
•Active or prior documented of autoimmune disease requiring systemic therapy within 2 years prior to screening. Note: Enrollment is permitted in the following conditions: hypothyroidism that can be controlled by hormone replacement therapy alone, skin conditions that do not require systemic therapy (e.g. vitiligo, psoriasis), and controlled celiac disease.
•Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily ) or other immunosuppressive medications within 14 days of first study drug administration (topical or physiological hormones dose is acceptable)
•Receipt of any systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is longer) prior to first dose, small molecule tyrosine kinase-targeted agents therapy or immunomodulatory therapy within 2 weeks prior to first dose; or herbal or proprietary Chinese medicines with antitumor indications within 1 week prior to the first dose.
•For hepatocellular carcinoma: receipt of local area treatment of the liver within 4 weeks prior to the first dose of B1962
•History of organ or hematopoietic stem cell transplantation requiring immunosuppressive medications
•History of other neoplasms within 5 years prior to screening, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cervical cancer in situ that has undergone successful radical surgery
•Received attenuated vaccination within 4 weeks prior to screening or planning to receive attenuated vaccination during the study period
•Patients who have participated in a clinical study and received study drug within 4 weeks or 5 half-lives (whichever is longer) prior to the first dose
•History of alcohol or drug abuse within 12 months prior to the first dose.
•Known history of psychiatric disorder that may affect trial compliance
•Other serious systemic disease, abnormal laboratory tests, or other reasons deemed inappropriate for subjects by the investigator

干预措施: B1962 (Drug)

结局指标

主要结局

DLT Assessment

时间窗: From Day1 to Day15 after first dose of B1962

Toxicity associated with the treatment of the investigational drug B1962

AE Assessment

时间窗: From first dose of B1962 until 28 days after the last dose of B1962.

The frequency of AE

12-lead ECG Assessment

时间窗: From first dose of B1962 until 28 days after the last dose of B1962.

Changes of 12-lead ECG from baseline

Eastern Cooperative Oncology Group score Assessment

时间窗: From first dose of B1962 until 28 days after the last dose of B1962.

Changes of Eastern Cooperative Oncology Group score from baseline

Determine the maximum tolerated dose (MTD)

时间窗: From first dose of B1962 until 28 days after the last dose of B1962

Determine the recommended phase II dose (RP2D)

时间窗: From first dose of B1962 until 28 days after the last dose of B1962

次要结局

Peak Plasma Concentration (Cmax) Analysis(From first dose of B1962 through 7 days of deciding to stop research treatment by subjects)
Area under the plasma concentration versus time curve (AUC) Analysis(From first dose of B1962 through 7 days of deciding to stop research treatment by subjects)
Terminal elimination half-life(t1/2) Analysis(From first dose of B1962 through 7 days of deciding to stop research treatment by subjects)
Time to reach the maximum observed concentration(Tmax) Analysis(From first dose of B1962 through 7 days of deciding to stop research treatment by subjects)
Number of subjects who develop detectable anti-drug antibodies (ADAs)(From first dose of B1962 until 28 days after the last dose of B1962)

研究者

发起方

Tasly Biopharmaceuticals Co., Ltd.

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

招募中

1 期

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid TumorsHead and Neck CancerMalignant MelanomaColorectal CancerCervical CancerRenal Cell CarcinomaBreast Cancer

NCT06265025GeneMedicine Co., Ltd.125

进行中（未招募）

1 期

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaB-cell Non Hodgkin LymphomaDiffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma

NCT04594642AstraZeneca226

尚未招募

1 期

A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid TumorsAdvanced Solid Tumor

NCT05344742CSPC ZhongQi Pharmaceutical Technology Co., Ltd.116

已完成

1 期

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid TumorsAdvanced Cancer

NCT03352531Akesobio Australia Pty Ltd99

已完成

1 期

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid TumorsAdvanced Cancer

NCT03261011Akesobio Australia Pty Ltd119